Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [10/16/2026 14:56 PDT] Pharvaris N.V. (NASDAQ:PHVS), Down By 100% ($30.02) From $30.02 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [10/16/2026 12:42 PDT] Pharvaris N.V. (NASDAQ:PHVS), Down By 100% ($30.49) From $30.49 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [10/14/2026 06:14 PDT] PHVS Expected to Trade Down Short Term
• [10/06/2026 06:20 PDT] PHVS Expected to Trade Down Short Term
• [10/02/2026 06:11 PDT] PHVS Expected to Trade Down Short Term
• [09/10/2026 05:25 PDT] PHVS Expected to Trade Up After Bullish Patterns Develop
• [08/26/2026 07:38 PDT] PHVS Expected to Trade Up After Bullish Patterns Develop